Partner/Chief Technology Officer
Craig Muir joined Third Rock Ventures in 2007 and has more than 25 years of technology development, implementation and application experience across the biotechnology and pharmaceutical industries. He leads the identification and integration of drug discovery and development technology platforms for companies across our portfolio, provides solutions for developing platform systems to manage R&D and informatics, and contributes to scientific diligence for investment opportunities. Craig has been instrumental in expanding our San Francisco presence to increase access to innovative technologies and support our West Coast companies. Craig also assumes leadership roles in our portfolio companies, serving as interim chief technology or information officer through the first 12-18 months after launch:
- Interim chief technology officer of Cedilla Therapeutics
- Interim chief technology officer of Pliant Therapeutics
- Board of directors observer for CytomX Therapeutics
- Board member of Decibel Therapeutics
- Former interim chief technology officer of Constellation Pharmaceuticals
- Former interim chief technology officer of Global Blood Therapeutics
Prior to Third Rock, Craig served as senior vice president of technical operations for Codon Devices. Before that, he spent 12 years at Millennium Pharmaceuticals as vice president of platform technology where his teams were instrumental in raising $1.8 billion from pharmaceutical partners. Earlier in his career, Craig served in a number of technology development and scientific roles at Genentech, Tularik and the University of Vermont. Craig completed his B.S. in animal physiology at the University of California, Davis and is a pioneer in the fields of laboratory automation and technology in biotech and pharmaceutical applications. Craig serves on the Scientific Advisory Board of the Bigelow Laboratory for Ocean Sciences.
Craig has donated more than six gallons of blood to Boston Children’s Hospital and other donation centers.